<DOC>
	<DOCNO>NCT01016041</DOCNO>
	<brief_summary>Instead treat in-stent restenosis , best strategy patient prevent in-stent restenosis . Recent advance understand cellular mechanism responsible smooth muscle cell proliferation ( neointimal hyperplasia ) , together improvement stent coat elute technology provide scientific background develop drug elute stent . Drug elute stent ( DES ) promising development interventional cardiology . Different class drug mount polymer layer surface stent show effective prevent neointimal hyperplasia . Currently 7 DES stent CE mark commercially available market . Two stent , respectively sirolimus elute Cypher™ stent paclitaxel elute Taxus™ stent , clinical use since 2002 . The Cypher™ stent consist Bx sonic stent/balloon platform . The stent coat non-degradable biocompatible PBMA/PEVA polymer elute sirolimius . The Taxus™ stent consist Express2 balloon/stent platform coat non-degradable biocompatible Translute™ polymer elute paclitaxel . Recent large randomize trial like RAVEL , SIRIUS , E-SIRIUS C-SIRIUS ( Cypher™ versus bare metal BX sonic™ stent ) , TAXUS II , IV , V , VI ( Taxus versus bare metal Express™ stent ) show DES dramatically reduce incidence in-stent restenosis subsequently need target lesion revascularization patient non complex moderate long de-novo coronary lesion vessel diameter 2.5 -3.5 mm.1-11 Considering encourage result early clinical trial far mid long term follow-up , need explore utilization DES subset coronary lesion like : long lesion , chronic total occlusion , venous graft lesion , thrombotic lesion , restenosis lesion , ostial bifurcation lesion lesion large vessel . As result previous report randomized trial , FDA regulatory institute require new DES evaluate one former DES ( Cypher Taxus ) . The XIENCE-V stent second generation DES , thinner flexible Cobalt-Chromium stent strut , compare first generation Stainless Steel stent strut Cypher Taxus . This study address question whether XIENCE-V™ stent superior clinical result Taxus™ stent general population refer percutaneous coronary intervention ( PCI ) . Objective study : The main objective study head tot head comparison everolimus coat XIENCE-V™ stent paclitaxel coat TAXUS™ stent order observe whether difference clinical outcome stent . Efficacy stent assess composite end point : death , non fatal myocardial infarction target vessel revascularization . Study design : Single center , randomise , open label study all-comers refer PCI . Study population : Approximately 1600 consecutive patient coronary artery disease eligible accord in- exclusion criterion enrol randomized 1:1 basis . Primary study parameters/outcome study : The primary end point study composite end point : death , non fatal myocardial infarction , target vessel revascularization 1 year . Secondary study parameters/outcome study : The secondary end point study : A ) The combine endpoint cardiac death , non fatal myocardial infarction , ischemic driven target lesion revascularization ( TLR ) rate 1 , 6 12 month follow-up . B ) The combined endpoint death , non fatal myocardial infarction , target vessel revascularization ( TVR ) rate 2 , 3 , 4 5 year . Nature extent burden risk associate participation , benefit group relatedness : The burden patient consist fill 8 questionnaire ( 1 A4 per questionnaire ) 5 year time . The first 3 questionnaire first year also request monitoring purpose Ministry Health Dutch Cardiology Society ( Nederlandse Vereniging Voor Cardiologie ; NVVC ) . There risk patient relate participation study . The patient receive Taxus Xience-V stent anyhow , indication DES stent exists .</brief_summary>
	<brief_title>A Trial Everolimus-eluting Stents Paclitaxel-eluting Stents Coronary Revascularization Daily Practice : The COMPARE Trial</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Any patient 18 85 year lesions feasible PCI treatment . Dual antiplatelet therapy contraindication , Participation trial , No inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>stable angina</keyword>
	<keyword>ACS</keyword>
	<keyword>MACE</keyword>
	<keyword>safety</keyword>
	<keyword>stent thrombosis</keyword>
</DOC>